1
|
Suzuki A, Shibata N, Kasanuki K, Nagata T, Shinagawa S, Kobayashi N, Ohnuma T, Takeshita Y, Kawai E, Takayama T, Nishioka K, Motoi Y, Hattori N, Nakayama K, Yamada H, Arai H. Genetic Association between Presenilin 2 Polymorphisms and Alzheimer's Disease and Dementia of Lewy Body Type in a Japanese Population. Dement Geriatr Cogn Dis Extra 2016; 6:90-7. [PMID: 27065294 PMCID: PMC4821141 DOI: 10.1159/000444080] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Background/Aims Mutations in the presenilin 2 (PSEN2) gene cause familial Alzheimer's disease (AD). Common polymorphisms affect gene activity and increase the risk of AD. Nonsynonymous polymorphisms in the PSEN2 gene showed Lewy body dementia (LBD) phenotypes clinically. Therefore, we aimed to investigate whether PSEN2 gene polymorphisms were associated with AD or LBD. Methods Seven single nucleotide polymorphisms (SNPs) of the gene were analyzed using a case-control study design comprising 288 AD patients, 76 LBD patients, and 105 age-matched controls. Results Linkage disequilibrium (LD) examination showed strong LD from rs1295645 to rs8383 on the gene in our cases from Japan. There were no associations between the SNPs studied here and AD onset, and haplotypic analyses did not detect genetic associations between AD and the PSEN2 gene. Although the number of the cases was small, the SNPs studied did not modify the risk of developing LBD in a Japanese population. Conclusion The common SNPs of the PSEN2 gene did not affect the risk of AD or LBD in a Japanese population. Because genetic variability of the PSEN2 gene is associated with behavioral and psychological symptoms of dementia (BPSD) in AD and LBD, further detailed analyses considering BPSD of both diseases would be required.
Collapse
Affiliation(s)
- Ayako Suzuki
- Departments of Psychiatry, Juntendo University School of Medicine, Tokyo, Japan
| | - Nobuto Shibata
- Departments of Psychiatry, Juntendo University School of Medicine, Tokyo, Japan
| | - Koji Kasanuki
- Departments of Psychiatry, Juntendo University School of Medicine, Tokyo, Japan
| | - Tomoyuki Nagata
- Department of Psychiatry, Institute of DNA Medicine, Jikei University School of Medicine, Tokyo, Japan; Division of Molecular Genetics, Institute of DNA Medicine, Jikei University School of Medicine, Tokyo, Japan
| | - Shunichiro Shinagawa
- Department of Psychiatry, Institute of DNA Medicine, Jikei University School of Medicine, Tokyo, Japan
| | - Nobuyuki Kobayashi
- Department of Psychiatry, Institute of DNA Medicine, Jikei University School of Medicine, Tokyo, Japan
| | - Tohru Ohnuma
- Departments of Psychiatry, Juntendo University School of Medicine, Tokyo, Japan
| | - Yoshihide Takeshita
- Departments of Psychiatry, Juntendo University School of Medicine, Tokyo, Japan
| | - Eri Kawai
- Departments of Psychiatry, Juntendo University School of Medicine, Tokyo, Japan
| | - Toshiki Takayama
- Departments of Psychiatry, Juntendo University School of Medicine, Tokyo, Japan
| | - Kenya Nishioka
- Departments of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - Yumiko Motoi
- Departments of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - Nobutaka Hattori
- Departments of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - Kazuhiko Nakayama
- Department of Psychiatry, Institute of DNA Medicine, Jikei University School of Medicine, Tokyo, Japan
| | - Hisashi Yamada
- Division of Molecular Genetics, Institute of DNA Medicine, Jikei University School of Medicine, Tokyo, Japan
| | - Heii Arai
- Departments of Psychiatry, Juntendo University School of Medicine, Tokyo, Japan
| |
Collapse
|